… Cardiovascular Disease targeting B4GALT1 Development of Axiomer ® RNA base editing technology platform continues … with successful defense of opposition against a key Axiomer patent protecting ADAR-mediated RNA editing … against our strategy to accelerate the development of Axiomer,” said Daniel A. de Boer, Chief Executive Officer of …
… strategy to focus on accelerating the development of Axiomer ® RNA base-editing technology platform across … RNA editing technology – Accelerate development of the Axiomer ® RNA base-editing technology platform, including an … The Company will accelerate the development of its Axiomer ® RNA editing platform and pipeline activities and …
… transformative RNA therapies based on its proprietary Axiomer® RNA editing technology platform, today announced … webcast will be available for approximately 30 days. About Axiomer ® ProQR is pioneering a next-generation RNA base …
… transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the … register as described in the notice and agenda. About Axiomer ™ ProQR is pioneering a next-generation RNA base …
… transformative RNA therapies based on its proprietary Axiomer® RNA editing technology platform, today announced the … has served on ProQR’s Supervisory Board since 2014. About Axiomer ® ProQR is pioneering a next-generation RNA base …
… transformative RNA therapies based on its proprietary Axiomer ™ RNA editing technology platform today announced … will then be available for approximately 30 days. About Axiomer ™ ProQR is pioneering a next-generation RNA base editing technology called Axiomer ™ , which could potentially yield a new class of …
… ophthalmic programs supports ProQR’s strategic focus on Axiomer® RNA editing platform technology and continued … transformative RNA therapies based on its proprietary Axiomer ® RNA editing technology platform, today reported its …